现代医药卫生
現代醫藥衛生
현대의약위생
Journal of Modern Medicine & Health
2015年
20期
3053-3055
,共3页
体层摄影术,X线%诊断显像%卵巢肿瘤%抗原,肿瘤相关%碳水化合物%肿瘤分期
體層攝影術,X線%診斷顯像%卵巢腫瘤%抗原,腫瘤相關%碳水化閤物%腫瘤分期
체층섭영술,X선%진단현상%란소종류%항원,종류상관%탄수화합물%종류분기
Tomography,X-ray%Diagnostic imaging%Ovarian neoplasma%Antigens,tumor-associated%Carbohy-drate%Neoplasm staging
目的：探讨动态增强CT联合糖链抗原19-9（CA19-9）、癌抗原125（CA125）检查在卵巢癌诊断及分期中的价值。方法对56例卵巢癌患者行动态增强CT检查及术前血清CA19-9、CA125水平检测，结合术后病理及临床分期进行分析比较。结果动态增强CT诊断符合率为85.7%，CA19-9诊断符合率为60.7%，CA125诊断符合率为71.4%，三者联合诊断法诊断符合率为94.6%，三者联合诊断法诊断符合率与单项诊断法比较，差异均有统计学意义（P<0.05）。动态增强CT分期与临床分期诊断符合率为Ⅰ期86.7%、Ⅱ期85.7%、Ⅲ+Ⅳ期72.4%；CA19-9分期与临床分期诊断符合率为Ⅰ期53.8%、Ⅱ期77.8%、Ⅲ+Ⅳ期31.0%；CA125分期与临床分期诊断符合率为Ⅰ期76.9%、Ⅱ期85.7%、Ⅲ+Ⅳ期62.1%；联合诊断法分期与临床分期诊断符合率为Ⅰ期92.3%、Ⅱ期93.3%、Ⅲ+Ⅳ期89.7%，Ⅲ+Ⅳ期三者联合诊断法与其余单项诊断法比较，差异均有统计学意义（P<0.01）。结论动态增强CT联合CA19-9、CA125检查能够较敏感及准确地发现卵巢癌，对临床诊断有着重要帮助，并为卵巢癌的准确临床分期提供客观依据。
目的：探討動態增彊CT聯閤糖鏈抗原19-9（CA19-9）、癌抗原125（CA125）檢查在卵巢癌診斷及分期中的價值。方法對56例卵巢癌患者行動態增彊CT檢查及術前血清CA19-9、CA125水平檢測，結閤術後病理及臨床分期進行分析比較。結果動態增彊CT診斷符閤率為85.7%，CA19-9診斷符閤率為60.7%，CA125診斷符閤率為71.4%，三者聯閤診斷法診斷符閤率為94.6%，三者聯閤診斷法診斷符閤率與單項診斷法比較，差異均有統計學意義（P<0.05）。動態增彊CT分期與臨床分期診斷符閤率為Ⅰ期86.7%、Ⅱ期85.7%、Ⅲ+Ⅳ期72.4%；CA19-9分期與臨床分期診斷符閤率為Ⅰ期53.8%、Ⅱ期77.8%、Ⅲ+Ⅳ期31.0%；CA125分期與臨床分期診斷符閤率為Ⅰ期76.9%、Ⅱ期85.7%、Ⅲ+Ⅳ期62.1%；聯閤診斷法分期與臨床分期診斷符閤率為Ⅰ期92.3%、Ⅱ期93.3%、Ⅲ+Ⅳ期89.7%，Ⅲ+Ⅳ期三者聯閤診斷法與其餘單項診斷法比較，差異均有統計學意義（P<0.01）。結論動態增彊CT聯閤CA19-9、CA125檢查能夠較敏感及準確地髮現卵巢癌，對臨床診斷有著重要幫助，併為卵巢癌的準確臨床分期提供客觀依據。
목적：탐토동태증강CT연합당련항원19-9（CA19-9）、암항원125（CA125）검사재란소암진단급분기중적개치。방법대56례란소암환자행동태증강CT검사급술전혈청CA19-9、CA125수평검측，결합술후병리급림상분기진행분석비교。결과동태증강CT진단부합솔위85.7%，CA19-9진단부합솔위60.7%，CA125진단부합솔위71.4%，삼자연합진단법진단부합솔위94.6%，삼자연합진단법진단부합솔여단항진단법비교，차이균유통계학의의（P<0.05）。동태증강CT분기여림상분기진단부합솔위Ⅰ기86.7%、Ⅱ기85.7%、Ⅲ+Ⅳ기72.4%；CA19-9분기여림상분기진단부합솔위Ⅰ기53.8%、Ⅱ기77.8%、Ⅲ+Ⅳ기31.0%；CA125분기여림상분기진단부합솔위Ⅰ기76.9%、Ⅱ기85.7%、Ⅲ+Ⅳ기62.1%；연합진단법분기여림상분기진단부합솔위Ⅰ기92.3%、Ⅱ기93.3%、Ⅲ+Ⅳ기89.7%，Ⅲ+Ⅳ기삼자연합진단법여기여단항진단법비교，차이균유통계학의의（P<0.01）。결론동태증강CT연합CA19-9、CA125검사능구교민감급준학지발현란소암，대림상진단유착중요방조，병위란소암적준학림상분기제공객관의거。
Objective To explore the value of dynamic enhanced CT combined with CA19-9 and CA125 detection in the diagnosis and staging of ovarian cancer. Methods 56 cases of ovarian cancer were performed the dynamic enhanced CT exami-nation and detection of preoperative serum CA19-9 and CA125 levels. The detection results were analyzed and compared by com-bining the postoperative pathology and clinical staging. Results The diagnosis coincidence rate of dynamic enhanced CT was 85.7%,which of CA19-9 and CA125 were 60.7%and 71.4%respectively;which of the 3-item combination was 94.6%,the differ-ences between the 3-item combination detection and the single item detection were statistically significant (P<0.05). The diagnosis coincidence rates of dynamic enhanced CT staging and clinical staging were 86.7%for stageⅠ,85.7%for stageⅡand 72.4%for stageⅢ+Ⅳ;which of CA19-9 staging and clinical staging were 53.8%for stageⅠ,77.8%for stageⅡand 31.0%for stageⅢ+Ⅳ;which of CA125 staging and clinical staging were 76.9%for stageⅠ,85.7%for stageⅡand 62.1%for stageⅢ+Ⅳ;which of the combined diagnosis staging and clinical staging were 92.3%for stageⅠ,93.3%for stageⅡand 89.7%for stageⅢ+Ⅳ,showing that the differences between the 3-item combination diagnosis method and the other single diagnosis methods for the stage Ⅲ+Ⅳwere statistically significant(P<0.01). Conclusion Dynamic enhanced CT combined with CA19-9 and CA125 detection can more sensitively and accurately discover ovarian cancer ,has important help to clinical diagnosis and provides the objective basis for the accurate clinical stage of ovarian cancer.
